Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease

Alzheimer's and Dementia

Volumn 10, Issue 6, 2014, Pages 690-703

  Dodge, Hiroko H ^a,b,c   Zhu, Jian ^b   Harvey, Danielle ^d   Saito, Naomi ^d   Silbert, Lisa C ^a,e   Kaye, Jeffrey A ^a,e   Koeppe, Robert A ^f   Albin, Roger L ^b,c,g  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

ADNI; ADNI exe; ADNI mem; Biomarker; Biomarker progressions; Cognitive declines; FDG PET; MCI; MRI volume

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE; TAU PROTEIN; FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE NEUROIMAGING INITIATIVE STUDY; ARTICLE; BRAIN SIZE; BRAIN VENTRICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA ASSESSMENT; DISEASE COURSE; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; COGNITION DISORDERS; COMPLICATION; FACTUAL DATABASE; LONGITUDINAL STUDY; MENTAL HEALTH; METABOLISM; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; COGNITION DISORDERS; DATABASES, FACTUAL; DISEASE PROGRESSION; EXECUTIVE FUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84927174962     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.04.513     Document Type: Article

References (37)

1. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, and P.S. Aisen Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
2. C.R. Jack, D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
3. V.L. Villemagne, S. Burnham, and P. Bourgeat Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367
4. N.H. Stricker, H.H. Dodge, N.M. Dowling, S.D. Han, E.A. Erosheva, and W.J. Jagust CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade Brain Imaging Behav 6 2012 599 609
5. J.C. Morris The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 43 1993 2412 2414
6. R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, and E. Kokmen Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 1999 303 308
7. R.C. Petersen, and J.C. Morris Mild cognitive impairment as a clinical entity and treatment target Arch Neurol 62 2005 1160 1163
8. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
9. W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, and C.A. Mathis The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core Alzheimers Dement 6 2010 221 229
10. J.Q. Trojanowski, H. Vandeerstichele, M. Korecka, C.M. Clark, P.S. Aisen, and R.C. Petersen Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects Alzheimers Dement 6 2010 230 238
11. R.C. Petersen, P.S. Aisen, L.A. Beckett, M.C. Donohue, A.C. Gamst, and D.J. Harvey Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization Neurology 74 2010 201 209
12. R.S. Desikan, F. Segonne, B. Fischl, B.T. Quinn, B.C. Dickerson, and D. Blacker An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest Neuroimage 31 2006 968 980
13. B.C. Dickerson, E. Feczko, J.C. Augustinack, J. Pacheco, J.C. Morris, and B. Fischl Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area Neurobiol Aging 30 2009 432 440
14. S.M. Landau, D. Harvey, C.M. Madison, R.A. Koeppe, E.M. Reiman, and N.L. Foster Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI Neurobiol Aging 32 2011 1207 1218
15. L.E. Gibbons, A.C. Carle, R.S. Mackin, D. Harvey, S. Mukherjee, and P. Insel A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment Brain Imaging Behav 6 2012 517 527
16. P.K. Crane, A. Carle, L.E. Gibbons, P. Insel, R.S. Mackin, and A. Gross Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav 6 2012 502 516
17. 18F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease Brain Imaging Behav 6 2012 568 583
18. D.B. Howieson, N.E. Carlson, M.M. Moore, D. Wasserman, C.D. Abendroth, and J. Payne-Murphy Trajectory of mild cognitive impairment onset J Int Neuropsychol Soc 14 2008 192 198
19. H.H. Dodge, C.N. Wang, C.C. Chang, and M. Ganguli Terminal decline and practice effects in older adults without dementia: the MoVIES project Neurology 77 2011 722 730
20. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
21. S.M. Landau, M.A. Mintun, A.D. Joshi, R.A. Koeppe, R.C. Petersen, and P.S. Aisen Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol 72 2012 578 586
22. G.D. Rabinovici, and W.J. Jagust Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo Behav Neurol 21 2009 117 128
23. V. Dore, V.L. Villemagne, P. Bourgeat, J. Fripp, O. Acosta, and G. Chetelat Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease JAMA Neurol 70 2013 903 911
24. J.A. Becker, T. Hedden, J. Carmasin, J. Maye, D.M. Rentz, and D. Putcha Amyloid-beta associated cortical thinning in clinically normal elderly Ann Neurol 69 2011 1032 1042
25. B.S. Ye, S.W. Seo, J.J. Yang, H.J. Kim, Y.J. Kim, and C.W. Yoon Comparison of cortical thickness in patients with early-stage versus late-stage amnestic mild cognitive impairment Eur J Neurol 21 2014 86 92
26. J.D. Grill, L. Di, P.H. Lu, C. Lee, J. Ringman, and L.G. Apostolova Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative Neurobiol Aging 34 2013 62 72
27. L.C. Silbert, H.H. Dodge, L.G. Perkins, L. Sherbakov, D. Lahna, and D. Erten-Lyons Trajectory of white matter hyperintensity burden preceding mild cognitive impairment Neurology 79 2012 741 747
28. D. Mungas, D. Harvey, B.R. Reed, W.J. Jagust, C. DeCarli, and L. Beckett Longitudinal volumetric MRI change and rate of cognitive decline Neurology 65 2005 565 571
29. D.M. van den Heuvel, V.H. ten Dam, A.J. de Craen, F. Admiraal-Behloul, H. Olofsen, and E.L. Bollen Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population J Neurol Neurosurg Psychiatry 77 2006 149 153
30. O. Carmichael, C. Schwarz, D. Drucker, E. Fletcher, D. Harvey, and L. Beckett Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 67 2010 1370 1378
31. L.C. Silbert, C. Nelson, D.B. Howieson, M.M. Moore, and J.A. Kaye Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline Neurology 71 2008 108 113
32. J.H. Kramer, D. Mungas, B.R. Reed, M.E. Wetzel, M.M. Burnett, and B.L. Miller Longitudinal MRI and cognitive change in healthy elderly Neuropsychology 21 2007 412 418
33. W.T. Longstreth Jr., A.M. Arnold, N.J. Beauchamp Jr., T.A. Manolio, D. Lefkowitz, and C. Jungreis Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study Stroke 36 2005 56 61
34. E.J. van Dijk, N.D. Prins, H.A. Vrooman, A. Hofman, P.J. Koudstaal, and M.M. Breteler Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study Stroke 39 2008 2712 2719
35. L.C. Silbert, D.B. Howieson, H. Dodge, and J.A. Kaye Cognitive impairment risk: white matter hyperintensity progression matters Neurology 73 2009 120 125
36. N.D. Prins, E.J. van Dijk, T. den Heijer, S.E. Vermeer, J. Jolles, and P.J. Koudstaal Cerebral small-vessel disease and decline in information processing speed, executive function and memory Brain 128 2005 2034 2041
37. E.C. van Straaten, D. Harvey, P. Scheltens, F. Barkhof, R.C. Petersen, and L.J. Thal Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia J Neurol 255 2008 1302 1308